

1 Dose-response effect of dietary nitrate on muscle contractility
2 and blood pressure in older subjects
3
4

5 Edgar J. Gallardo¹, Derrick A. Gray¹, Richard L. Hoffman¹,
6 ¹Brandon A. Yates, ²Ranjani N. Moorthi, and Andrew R. Coggan¹
7
8

9 ¹Department of Kinesiology, School of Health and Human Science,
10 and ²Department of Internal Medicine, School of Medicine,
11 Indiana University Purdue University Indianapolis
12 Indianapolis, IN 46112
13
14

15 Address correspondence to: Andrew R. Coggan, PhD
16 Department of Kinesiology
17 Indiana University Purdue University Indianapolis
18 IF 101C, 250 University Boulevard
19 Indianapolis, IN 46112
20 Phone: (317) 274-0656
21 Fax: (317) 274-2041
22 e-mail: acoggan@iupui.edu

23 **Abstract**

24 **Purpose:** We have recently demonstrated that dietary nitrate, a source of nitric oxide via the
25 enterosalivary pathway, can improve muscle contractile function in healthy older men and
26 women. Nitrate ingestion has also been shown to reduce blood pressure in some, but not all,
27 studies of older individuals. However, the optimal dose for eliciting these beneficial effects is
28 unknown. **Methods:** A randomized, double-blind, placebo-controlled crossover study was
29 performed to determine the effects of ingesting 3.3 mL/kg of concentrated beetroot juice (BRJ)
30 containing 0, 200, or 400 $\mu\text{mol/kg}$ of nitrate in nine healthy older subjects (one man, eight
31 women; mean age 70 ± 1 y). Maximal knee extensor power (P_{max}) and speed (V_{max}) were
32 measured 2 h after BRJ ingestion using isokinetic dynamometry. Blood pressure was monitored
33 periodically throughout each study. **Results:** P_{max} (in W/kg) was higher ($P<0.05$) after the low
34 dose (3.9 ± 0.4) compared to the placebo (3.7 ± 0.4) or high dose (3.7 ± 0.4). V_{max} (in rad/s) also
35 tended higher ($P=0.08$) in the low (11.9 ± 0.7) compared to the placebo (10.8 ± 0.8) or high dose
36 (11.2 ± 0.8) trials. Eight out of nine subjects achieved a higher P_{max} and V_{max} after the lower vs.
37 the higher dose. These dose-related changes in muscle contractility paralleled changes in nitric
38 oxide (NO) bioavailability, as reflected by changes in breath NO and plasma 3-nitrotyrosine
39 levels. No significant changes were found in systolic, diastolic, or mean arterial pressure.

40 **Conclusions:** Varying doses of dietary nitrate have differential effects on muscle function and
41 blood pressure in older individuals. A moderate dose of nitrate increases muscle speed and
42 power, but these improvements are lost at a higher dose. Blood pressure, on the other hand, is not
43 reduced even with a higher dose.

44

45 Key words: Nitric oxide, nitrite, isokinetic dynamometry, 3-nitrotyrosine

46 Roughly $\frac{1}{3}$ of individuals over age 65 y suffer from some form of ambulatory or self-care
47 disability (1). In the United States alone, this amounts to some 15 million individuals at present,
48 a number is likely to at least double over the next three decades (1). Similar trends are evident
49 world-wide (1). The primary cause of disability in older persons is a decline in muscle contractile
50 function, with serious difficulty walking or climbing stairs being the most prevalent problem at
51 all ages (1). These functional limitations are highly predictive of dependence, institutionalization,
52 and mortality in the elderly (2,3). Thus, it is clear that age-related changes in muscle function can
53 have an enormous impact not only on a given individual's quality and length of life but also on
54 the societal costs of caring for an aging population.

55 Numerous factors contribute to the decline in muscle contractile function with aging.
56 These include a reduction in overall muscle mass, as a result of a decrease in both muscle fiber
57 number and size, as well as alterations in the neural control of muscle (4,5). These contribute to a
58 decrease in strength, i.e., a reduction in the maximal force-generating capacity of muscle.
59 However, the maximal speed of muscle shortening also decreases with aging (6-9), leading to an
60 even more dramatic age-related decline in maximal muscle power, i.e., the product of force and
61 speed (7,8). Moreover, decreases in muscle power with aging are a better predictor of movement
62 disabilities than decreases in strength (9,10). Improving muscle speed and power should
63 therefore logically be the primary focus of any intervention intended to combat muscle
64 dysfunction in the elderly.

65 We have previously reported that dietary nitrate (NO_3^-), a source of nitric oxide (NO) via
66 the reduction of NO_3^- to nitrite (NO_2^-) and hence to NO via the action of bacterial NO_3^-
67 reductases in the mouth and/or mammalian NO_3^- reductases (e.g., xanthine oxidase (XOR)) in
68 the tissues (10), can significantly enhance muscle speed and power in various subject

69 populations, i.e., healthy young and middle-aged individuals (11,12), athletes (13), patients with
70 heart failure (14). Although the exact mechanisms responsible for this effect are still uncertain,
71 they appear to involve NO-mediated changes in muscle calcium (Ca^{2+}) release and/or sensitivity
72 (15). More recently, we have demonstrated that acute NO_3^- ingestion also significantly improves
73 muscle speed and power in healthy elderly subjects (16). These changes were large enough to
74 theoretically offset the reductions resulting from several decades of aging. It is therefore clear
75 that dietary NO_3^- supplementation holds enormous potential as a means of mitigating muscle
76 dysfunction, and hence disability, in older individuals. The optimal dose of NO_3^- for eliciting
77 improvements in muscle contractility in elderly persons, however, has not been determined.

78 In addition to improving muscle function, dietary NO_3^- supplementation has also been
79 found to reduce blood pressure in a number of subject groups (17). However, a recent meta-
80 analysis concluded that dietary NO_3^- does not reduce blood pressure in subjects ≥ 65 y of age
81 (18). It was hypothesized that this may be due to variations in the oral microbiota and/or other
82 factors (e.g., gastric acid production) that could influence the extent of reduction of NO_3^- to NO_2^-
83 (18). Alternatively, an age-related decline in the expression of the putative NO_3^- transporter
84 sialin could limit the ability of the salivary glands of older individuals to concentrate and re-
85 secrete NO_3^- into the oral cavity (19). In either case, larger doses of NO_3^- may be required to
86 elicit significant increases in plasma NO_2^- levels and NO bioavailability, and hence a decrease in
87 blood pressure, in older persons. As with muscle function, however, the effect of NO_3^- dose on
88 changes in blood pressure in older individuals has not been tested.

89 The purpose of the present study was to determine the effects of varying doses of dietary
90 NO_3^- on changes in muscle speed and power and blood pressure in healthy older men and
91 women. Based on previous research (20), we hypothesized that a moderate dose of NO_3^- would

92 increase muscle speed and power in such individuals, which would not be further enhanced at a
93 higher dose of NO_3^- . Blood pressure, on the hand, would only be significantly reduced at a
94 higher dose of NO_3^- .

95 **Methods**

96 *Subjects:* Nine healthy, community-dwelling older subjects (one man, eight women) with mean
97 (\pm SE) age, height, weight, and body mass index of 70 ± 1 y, 1.68 ± 0.03 m, 68.7 ± 4.2 kg, and
98 24.3 ± 1.3 kg/m^2 participated in this study. Potential subjects were assessed during an initial visit
99 to the Clinical Research Center that included a health history and physical examination, resting
100 electrocardiogram, phlebotomy for determination of screening/phenotyping laboratories (CBC,
101 CMP, fasting insulin and lipids), and practicing the entire isokinetic dynamometry testing
102 protocol (see below). Individuals were excluded if they met any of the following criteria: not
103 between the ages of 65-79 y, unable to provide informed consent, were pregnant or lactating, had
104 a history of major metabolic (Type I or II diabetes, thyroid disorders), neuromuscular (e.g.,
105 cervical spondylotic radiculomyelopathy, lumbar spondylosis, amyotrophic lateral sclerosis,
106 Guillain-Barré syndrome, acquired demyelinating polyneuropathies), cardiovascular (e.g.,
107 moderate or severe valvular disease, myocardial infarction/ischemia, myocardial/pericardial
108 disease, stage II or greater hypertension, heart failure), renal (eGFR < 60 mL/min/1.73 m^2 or 61-
109 90 mL/min/1.73m^2 and albumin:creatinine ratio > 30), or liver (i.e., SGOT/SGPT > 2 x normal)
110 disease, were anemic (hematocrit $< 30\%$), or had any other contraindications to vigorous
111 exercise. They were also excluded from the study if they currently smoked or were taking proton
112 pump inhibitors, antacids, xanthine oxidase inhibitors, or were on hormone replacement therapy,
113 as these can interfere with the reduction of NO_3^- to NO_2^- and then NO (21-23). Individuals on
114 phosphodiesterase inhibitors were also excluded, as these can potentiate the effects of NO (24).

115 The study was approved by the Human Subjects Office at Indiana University, and written,
116 informed consent was obtained from each subject.

117 *Experimental design and protocol:* Following completion of the initial screening visit, eligible
118 volunteers were studied using a randomized, double-blind, placebo-controlled crossover design.
119 They were asked to avoid sympathetic stimulation (caffeine, alcohol) and fast for 12 h prior to
120 testing. Upon arrival at the University Hospital Clinical Research Center (CRC), blood pressure,
121 heart rate, and the amount of NO in the breath were measured. An intravenous catheter was then
122 placed, and a baseline blood sample was obtained for subsequent determination of plasma NO_3^-
123 and NO_2^- concentrations as described below. The subject then ingested 3.3 mL/kg of a
124 commercial concentrated beetroot juice (BRJ) supplementation (Beet It Sport[®], James White
125 Drinks, Ipswich, UK) either: 1) essentially devoid of NO_3^- (placebo); 2) containing (based on
126 direct measurement) 121 $\mu\text{mol/mL}$ NO_3^- (thus total dose = 400 $\mu\text{mol/kg}$); or 3) an equal mixture
127 of the placebo and NO_3^- containing BRJ products (total dose = 200 $\mu\text{mol/kg}$). Hemodynamic
128 data and breath/blood samples were collected again after 1 and 2 h of quiet rest, after which
129 muscle contractile function was determined as described below. After a 10 min recovery period,
130 heart rate and blood pressure were again measured and the final breath and blood samples were
131 collected, then the subject was fed lunch and released from the CRC. They subsequently returned
132 to the hospital and repeated the above procedures two more times receiving the other doses, with
133 a 1-2 wk washout period between visits.

134 *Measurement of muscle contractile function:* Maximal knee extensor power (P_{max} , in W/kg) and
135 velocity (V_{max} , in rad/s) were measured using an isokinetic dynamometer (Biodex System 4
136 Pro[®], Biodex Medical Systems, Shirley, NY) as previously described in detail (11). Briefly, the
137 femoral condyle of the subject's dominant leg was aligned with the axis of rotation of the

138 dynamometer and their torso, waist, thigh, and lower leg tightly restrained with straps to prevent
139 extraneous movement. The subject then performed maximal knee extensions at angular velocities
140 spanning the ascending limb of the power-velocity relationship, i.e., at 0, 1.57, 3.14, 4.71, and
141 6.28 rad/s (0, 90, 180, 270, and 360 %/sec). Three maximal repetitions were executed at each
142 velocity, with 2 min of rest allowed between each set of contractions. Subjects were instructed to
143 attempt to move as quickly and as forcefully as possible during each repetition, and strong verbal
144 encouragement was provided throughout the testing. To eliminate artifacts, the isokinetic
145 dynamometer data were windowed, filtered, and smoothed as previously described (11), after
146 which peak power at each velocity was calculated by multiplying the peak torque by velocity.
147 Pmax and Vmax were then determined by fitting an inverted parabola to the peak power-velocity
148 relationship (11).

149 *Measurement of breath NO and plasma NO₃⁻, NO₂⁻, and 3-NT:* Breath NO was measured using a
150 portable electrochemical analyzer (NIOX VERO[®], Circassia Pharmaceuticals, Mooresville, NC).
151 Plasma NO₃⁻ and NO₂⁻ were measured using a dedicated high performance liquid
152 chromatography system (ENO-30, Eicom USA, San Diego, CA) as previously described in detail
153 (25). Briefly, 25 μL of thawed plasma was mixed 1:1 with methanol, centrifuged at 4°C for 10
154 minutes at 10,000 g, and a 10 μL aliquot of the protein-poor supernatant injected into the HPLC.
155 Plasma NO₃⁻ and NO₂⁻ concentrations were calculated based on standard curves generated using
156 NIST-traceable standard solutions. Plasma 3-NT levels were determined using a commercial
157 ELISA kit (OxiSelect[™], Cell Biolabs, San Diego, CA).

158 *Sample size:* The required sample sizes to detect changes in Pmax and Vmax (the primary
159 outcome variables) were estimated based on the respective effect sizes observed in our recent
160 study (16) and assuming $\alpha = 0.05$ and $1 - \beta = 0.90$. These calculations indicated that n=11 would

161 be required to detect changes in Pmax, whereas n=6 would be required to detect changes in
162 Vmax. However, we were only able to study n=9 subjects before all non-essential research at our
163 institution was halted due to the COVID-19 pandemic.

164 *Statistical analyses:* Statistical analyses were performed using GraphPad Prism version 8.4.1
165 (GraphPad Software, La Jolla, CA). Normality of data distribution was tested using the
166 D'Agostino-Pearson omnibus test. Peak torque/power data and hemodynamic, breath NO,
167 plasma NO₃⁻, NO₂⁻, and 3-NT data were analyzed using two-way (i.e., dose x velocity or dose x
168 time, respectively) repeated measures ANOVA. Changes from baseline (average of 2 h and 10
169 min post-exercise values) in the latter variables as well as absolute values and changes in Vmax
170 and Pmax were analyzed using one-way ANOVA. Post-hoc testing was performed using the
171 Holm-Šidák multiple comparison procedure. P<0.05 was considered significant.

172 **Results**

173 *Markers of NO bioavailability:* Plasma NO₃⁻ and NO₂⁻ concentrations and breath NO levels did
174 not change following ingestion of the placebo BRJ, whereas ingestion of BRJ containing 200
175 μmol/kg of NO₃⁻ resulted in marked elevations in all three (Table 1, Fig. 1A-C). The magnitude
176 of the increases in plasma NO₃⁻ and NO₂⁻ over baseline were comparable to those observed in
177 previous studies using similar doses of NO₃⁻ (e.g., Ref. 20). Ingestion of BRJ containing twice as
178 much NO₃⁻ (i.e., 400 μmol/kg) resulted in almost exactly double the increase in plasma NO₃⁻ and
179 NO₂⁻ concentration (Table 1, Fig. 1A and 1B). In contrast, the level of NO in breath increased
180 less after the higher vs. the lower dose of NO₃⁻ (Table 1, Fig. 1C), although it was still elevated
181 compared to the placebo trial. Plasma 3-NT concentrations initially decreased then gradually
182 increased during all three trials (P<0.05), but these changes tended to be greater during the
183 placebo and low dose trials versus the high dose trial (Table 1, Fig. 1D).

184 *Muscle contractile function:* There were no significant effects of NO_3^- ingestion on knee
185 extensor peak torque, and hence peak power, at low to moderate angular velocities (i.e., at 0,
186 1.57, 3.14, or 4.71 rad/s; Table 2). In keeping with our previous results (16), however, ingestion
187 of BRJ containing a moderate amount of NO_3^- (i.e., 200 $\mu\text{mol/kg}$) resulted in a significant
188 increase in peak torque, and hence peak power, at the highest velocity tested (i.e., 6.28 rad/s)
189 (Table 2). This beneficial effect of acute NO_3^- supplementation on muscle contractile function
190 was lost when the NO_3^- dose was doubled to 400 $\mu\text{mol/kg}$ (Table 2). Correspondingly, P_{max} (in
191 W/kg) as calculated from these data was significantly higher ($P<0.05$) after the low dose
192 (3.9 ± 0.4) compared to the placebo (3.7 ± 0.4) or high dose (3.7 ± 0.4). V_{max} (in rad/s) also tended
193 higher ($P=0.08$) in the low (11.9 ± 0.7) compared to the placebo (10.8 ± 0.8) or high (11.2 ± 0.8)
194 trials. Eight out of nine subjects (including the one man) achieved a higher P_{max} and V_{max} after
195 ingestion of the lower vs. the higher dose of NO_3^- (Figs. 2A-D).

196 *Hemodynamics:* Heart rate did not change significantly over time or in response to ingestion of
197 varying amounts of NO_3^- (Table 3). Systolic and mean blood pressure, on the other hand,
198 decreased significantly over time (both $P<0.01$ for main effect), with such changes tending to be
199 greatest in the high dose trial (Table 3). However, neither the treatment main effects nor the
200 treatment x time interaction effects were statistically significant. Diastolic blood pressure did not
201 change significantly with either time or treatment.

202 **Discussion**

203 The purpose of the present study was to determine the effect of varying doses of dietary NO_3^- on
204 changes in muscle contractile function and blood pressure in healthy older individuals. We found
205 that a moderate dose of NO_3^- (i.e., 200 $\mu\text{mol/kg}$) resulted in measurable improvements in
206 maximal knee extensor speed and power, but no significant changes in blood pressure. A larger

207 dose of NO_3^- (i.e., 400 $\mu\text{mol}/\text{kg}$) also did not significantly alter blood pressure, whereas muscle
208 speed and power actually regressed towards, and in some individuals even below, baseline
209 values. This is the first dose-response study of the effects of acute dietary NO_3^- supplementation
210 on muscle contractile function in any population, and the first to specifically examine changes in
211 blood pressure in older subjects.

212 We have previously demonstrated that dietary NO_3^- supplementation can enhance muscle
213 contractility in a variety of subject populations (11-14). This includes healthy elderly men and
214 women, in whom acute intake of 13.4 ± 0.5 mmol (182 ± 10 $\mu\text{mol}/\text{kg}$) of NO_3^- increased maximal
215 knee extensor speed and power by 11 ± 2 and $4 \pm 4\%$, respectively (16). The results of the present
216 study are similar, in that V_{max} and P_{max} improved by 8 ± 4 and $7 \pm 3\%$, respectively, after
217 ingestion of BRJ containing 200 $\mu\text{mol}/\text{kg}$ of NO_3^- . The somewhat greater increase in P_{max} in the
218 present investigation vs. our previous study could be due to the slightly larger dose of NO_3^-
219 provided. Indeed, in our previous study we observed that individuals who received less than
220 ~ 150 $\mu\text{mol}/\text{kg}$ of NO_3^- were less likely to show significant improvements in muscle function
221 (unpublished observations). Alternatively, it could be due to the greater percentage of women in
222 the present study (i.e., 89 vs. 50%), as we have found that women tend to be more likely to
223 benefit from NO_3^- intake (12). Regardless, as previously discussed these improvements in muscle
224 function are substantial relative to their normal rate of decline with aging, and in fact are roughly
225 comparable to those resulting from several months of traditional resistance exercise training (cf.
226 Ref. 26 for review). As such, dietary NO_3^- supplementation could potentially have a measurable
227 impact on the functional capacity (e.g., walking speed, chair rise time, stair climbing ability) of
228 older persons during daily life, thus minimizing the risk of disability and dependence.

229 Given the latter, it is imperative to determine the optimal dose (and timing and source,
230 i.e., BRJ vs. a salt) of NO_3^- for enhancing muscle contractile function in older persons. Previous
231 dose-response studies in younger untrained or moderately-trained individuals have found that
232 providing 6-10 mmol (roughly 100-150 $\mu\text{mol}/\text{kg}$) of NO_3^- is generally sufficient to improve
233 economy and/or performance during endurance exercise (20,27-29), with no further
234 improvements at higher doses (i.e., up to 16.8 mmol, or $\sim 225 \mu\text{mol}/\text{kg}$) (20). As implied above,
235 however, it appears that somewhat higher doses of NO_3^- may be required to increase muscle
236 speed and power, at least in older men and women. Thus, in addition to studying a NO_3^- dose of
237 200 $\mu\text{mol}/\text{kg}$, we also tested subjects after they had consumed double this dose, i.e., 400
238 $\mu\text{mol}/\text{kg}$. Based on our previous research and that of Wylie et al. (20), we anticipated that this
239 would result in a quantitatively-similar improvement in muscle contractile function, i.e., that
240 both 200 and 400 $\mu\text{mol}/\text{kg}$ would fall on a plateau in the dose-response relationship.
241 Surprisingly, however, both V_{max} and P_{max} actually regressed at the higher dose, such that on
242 average they were not significantly different from the placebo trial. This pattern was highly
243 consistent across subjects, with all but one of the subjects performing best with the lower dose,
244 and several of the subjects actually performing worse following the higher dose than during the
245 placebo trial. To our knowledge, this is the first study to demonstrate a possible impairment in
246 exercise performance following ingestion of dietary NO_3^- , although both Larsen et al. (30) and
247 Bescós et al. (31) have previously reported that NO_3^- ingestion can reduce VO_2max .

248 The mechanism responsible for the above unanticipated finding is not clear. It does not,
249 however, appear to be due to failure of the higher dose of NO_3^- to further augment plasma NO_3^-
250 and NO_2^- levels, as both rose almost exactly twice as much following the 400 vs. the 200
251 $\mu\text{mol}/\text{kg}$ dose. This is consistent with the essentially complete bioavailability of NO_3^- from

252 ingested vegetables (32). Interestingly, however, the availability of NO itself, at least as
253 measured in the breath, rose less after the higher vs. the lower dose, and thus was significantly
254 lower in the former vs. the latter experiments. We therefore measured plasma 3-NT
255 concentrations, as another marker of the rate of NO production but also to determine whether the
256 higher dose of NO_3^- (which averaged 28.7 ± 2.7 mmol) resulted in “peaking over” of muscle
257 contractile function due to an increase in nitrosative stress. This possibility was suggested by the
258 recent results of Gholami et al. (33), who reported that ingestion of 24, but not 8 or 16, mmol of
259 NO_3^- resulted in a dramatic increase in plasma peroxynitrite levels in well-trained subjects
260 following a maximal incremental exercise test. In the present study, however, the pattern of
261 change in plasma 3-NT instead generally resembled that of breath NO, i.e., tending to increase
262 slightly after the lower dose but decrease slightly after the higher dose of NO_3^- .

263 We interpret the above findings as follows: the lower dose of NO_3^- significantly increased
264 plasma NO_3^- concentrations, which led to a rise in plasma (and presumably tissue (34)) NO_2^-
265 levels, and hence an increase in NO bioavailability. As a result of the latter, both muscle
266 contractile function (i.e., V_{max} and P_{max}) and plasma 3-NT concentrations were elevated (the
267 latter insignificantly) compared to the placebo trial. Conversely, the higher dose of NO_3^- resulted
268 in even greater increases in plasma NO_3^- and NO_2^- concentrations, but NO itself actually
269 increased less than after the lower dose, ostensibly as a result of NO_3^- outcompeting NO_2^- for
270 reduction by XOR. Consequently, muscle speed and power did not change significantly, whereas
271 plasma 3-NT concentrations actually tended to decline. This scenario, which is shown
272 schematically in Figure 3, is partially based on the observations of Damacena-Angelis et al. (35),
273 who found that higher concentrations of NO_3^- can inhibit XOR-mediated reduction of NO_2^- to
274 NO, and thus partially attenuate the blood pressure lowering effect of NO_2^- in rats. Although

275 speculative, the above hypothesis could explain the present observations. Alternatively, it is
276 possible that the high concentrations of NO_3^- and/or NO_2^- present after ingestion of the higher
277 dose led to a direct inhibitory effect on muscle contractile function, e.g., by enhancing
278 transnitrosylation of myosin (36). This would not, however, account for the lower NO levels
279 observed following ingestion of the higher dose of NO_3^- .

280 In contrast to the improvements in muscle speed and power observed following ingestion
281 of the lower dose of NO_3^- , blood pressure was unaltered by either the lower or the higher dose.
282 This finding is consistent with a recent meta-analysis by Siervo et al. (18) but runs counter to the
283 results of other studies of older subjects (37-39). The reason for these divergent results is
284 uncertain. The amount of NO_3^- provided in the present experiments is much higher than used in
285 these previous studies, such that an inadequate dose can seemingly be ruled out. It is possible
286 that the subjects we studied were resistant to the potential blood pressure-lowering effects of
287 dietary NO_3^- due to excessive oxidative stress, since NO_3^- plus ascorbic acid but not NO_3^- alone
288 has been reported to reduce systolic and mean arterial blood pressure in older adults (40). It is
289 also possible, however, that the failure to detect a statistically-significant NO_3^- -induced reduction
290 in blood pressure in the present study is simply a type 2 statistical error, due to the well-known
291 variability of blood pressure measurements combined with a relatively small number of subjects.
292 This is so because 1) changes in blood pressure from baseline were numerically greater after
293 NO_3^- ingestion (i.e., -8 ± 3 , -11 ± 4 , and -16 ± 4 , -1 ± 2 , -2 ± 2 , and -4 ± 2 , and -4 ± 2 , -5 ± 2 , and -8 ± 2
294 mmHg for systolic, diastolic, and mean arterial pressure in the placebo, 200 $\mu\text{mol/kg}$, and 400
295 $\mu\text{mol/kg}$ trials, respectively), and 2) post-hoc analysis of the data demonstrated that, given the
296 observed effect sizes, the achieved powers (i.e., $1-\beta$) with $n=9$ subjects were only 0.64, 0.67, and
297 0.83, respectively.

298 There are both strengths and weaknesses to the present study. A major strength is the use
299 of a highly-reliable method for assessing maximal muscle contractile properties, even in older
300 subjects. For example, as calculated from the ANOVA the intraclass correlation coefficient
301 (ICC) for Pmax was 0.98. This helps explain why we were able to detect statistically-significant
302 changes in muscle contractile function but not in, e.g., systolic blood pressure (ICC=0.70).
303 Another strength is that, unlike in previous dose-response studies (20,27-29), in the present
304 experiments the dose of NO₃⁻ was adjusted relative to body mass, thus at least theoretically
305 minimizing inter-subject variability in peak plasma NO₃⁻ concentrations due to differences in the
306 volume of distribution. At the same time, we kept the volume of BRJ the same across trials, thus
307 eliminating differences in the amount of other potentially biologically-active compounds (e.g.,
308 carotenoids, betalains, bioflavonoids, ascorbic acid) as a source of variability. As discussed
309 above, a weakness of our study is that it was slightly underpowered to detect possible differences
310 in blood pressure due to NO₃⁻ ingestion. Another weakness is that by studying only two doses of
311 NO₃⁻, i.e., 200 and 400 μmol/kg, it is not possible to determine whether the optimal dose is
312 somewhat less than 200 μmol/kg or somewhere between 200 and 400 μmol/kg. At a minimum,
313 however, the present data provide a starting point for further experiments.

314 In summary, in the present study we have examined the dose-response relationship
315 between dietary NO₃⁻ supplementation and changes in both muscle contractile function and
316 blood pressure in healthy older subjects. We found that although blood pressure was unchanged,
317 ingestion of a lower, but not a higher, dose of NO₃⁻ significantly increased maximal knee
318 extensor power, with these divergent results seemingly reflecting the failure of the higher dose to
319 sufficiently elevate NO bioavailability. Future studies should use the tools and approaches

320 commonly employed in pharmaceutical development (e.g., pharmacokinetic-pharmacodynamic
321 modeling) to further refine this possible treatment for muscle dysfunction in older persons.

322 **Conflicts of Interest and Source of Funding**

323 This work was supported by grants from the Office of the Vice Provost for Research at Indiana
324 University Purdue University Indianapolis and the National Institute on Aging (R21 AG053606)
325 to A.R. Coggan; the National Heart, Lung, and Blood institute (R34 HL138253) to A.R. Coggan
326 and Linda R. Peterson; the National Institute on Diabetes, Digestive, and Kidney Diseases (K23
327 DK102824) to R.N. Moorthi, the National Institute on Arthritis and Musculoskeletal and Skin
328 Disease (P30 AR072581) to Sharon Mo; and the National Center for Advancing Translational
329 Sciences (UL1 TR002529) to Anantha Shekhar. For the remaining authors no conflicts of
330 interest are declared. The contents of this article are solely the responsibility of the authors and
331 does not necessarily represent the official view of the National Institutes of Health or the
332 American College of Sports Medicine. The results of the study are presented clearly, honestly,
333 and without fabrication, falsification, or inappropriate data manipulation.

334 **References**

- 335 1. Roberts AW, Ogunwole SU, Blakeslee L, Rabe MA. U.S. Census Bureau, *American*
336 *Community Survey Reports, ACS-38, The Population 65 Years and Older in the United*
337 *States: 2016*, U.S. Government Publishing Office, Washington, DC, 2018.
- 338
- 339 2. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA,
340 Wallace RB. A short physical performance battery assessing lower extremity function:
341 association with self-reported disability and prediction of mortality and nursing home
342 admission. *J Gerontol.* 1994;49(2):M85–M94. <https://doi.org/10.1093/geronj/49.2.m85>
- 343
- 344 3. Roshanravan B, Patel KV, Fried LF, Robinson-Cohen C, de Boer IH, Harris T, Murphy RA,
345 Satterfield S, Goodpaster BH, Shlipak M, Newman AB, Kestenbaum B; Health ABC study.
346 Association of muscle endurance, fatigability, and strength with functional limitation and
347 mortality in the Health Aging and Body Composition study. *J Gerontol A Biol Sci Med Sci.*
348 2017;72(2):284-291. <https://doi.org/10.1093/gerona/glw210>
- 349
- 350 4. Reid KF, Fielding RA. Skeletal muscle power: A critical determinant of physical functioning
351 in older adults. *Exerc Sports Sci Rev.* 2012;40(1):4-40.
352 <https://doi.org/10.1097/JES.0b013e31823b5f13>
- 353
- 354 5. da Rosa Orssatto LB, Wiest MJ, Diefenthaler F. Neural and musculotendinous mechanisms
355 underpinning age-related force reductions. *Mech Ageing Dev* 2018;175(10):17-23.
356 <https://doi.org/10.1016/j.mad.2018.06.005>

- 357
- 358 6. Thompson BJ, Conchola EC, Palmer TB, Stock MS. Effects of aging on maximal and rapid
359 velocity capacities of the leg extensors. *Exp Gerontol.* 2014;58(10):128-131.
360 <https://doi.org/10.1016/j.exger.2014.07.019>
- 361
- 362 7. Valour D, Ochala J, Ballay Y, Pousson M. The influence of ageing on the force-velocity-
363 power characteristics of human elbow flexor muscles. *Exp Gerontol.* 2003;38(4):387-395.
364 [https://doi.org/10.1016/s0531-5565\(02\)00265-6](https://doi.org/10.1016/s0531-5565(02)00265-6)
- 365
- 366 8. Toji H, Kaneko M. Effects of aging on force, velocity, and power in the elbow flexors of
367 males. *J Physiol Anthropol.* 2007;26(11):587-592. <https://doi.org/10.2114/jpa2.26.587>
- 368
- 369 9. Pojednic RM, Clark DJ, Patten C, Reid K, Phillips EM, Fielding RA. The specific
370 contribution of force and velocity to muscle power in older adults. *Exp Gerontol.*
371 2012;47(8):608-612. <https://doi.org/10.1016/j.exger.2012.05.010>
- 372
- 373 10. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in
374 physiology and therapeutics. *Nat Rev Drug Discov.* 2008;7(2):156-167.
375 <https://doi.org/10.1038/nrd2466>
- 376
- 377 11. Coggan AR, Leibowitz JL, Kadkhodayan A, et al. Effect of acute dietary nitrate intake on
378 knee extensor speed and power in healthy men and women. *Nitric Oxide.* 2015;48(8):16-21.
379 <https://doi.org/10.1016/j.niox.2014.08.014>

380

381 12. Coggan AR, Broadstreet SR, Mikhalkova D, et al. Dietary nitrate-induced increases in
382 human muscle power: high versus low responders. *Physiol Rep.* 2018;6(2):e13575,
383 <https://doi.org/10.14814/phy2.13575>

384

385 13. Rimer EG, Peterson LR, Coggan AR, Martin JC. Acute dietary nitrate supplementation
386 increases maximal cycling power in athletes. *Int J Sports Physiol Perf.* 2016;11(6):715-720.
387 <https://doi.org/10.1123/ijsp.2015-0533>

388

389 14. Coggan AR, Leibowitz JL, Anderson Spearie C, et al. Acute dietary nitrate intake improves
390 muscle contractile function in patients with heart failure: a double-blind, placebo-controlled,
391 randomized trial. *Circ Heart Fail.* 2015;8(5):914-920.
392 <https://doi.org/10.1161/CIRCHEARTFAILURE.115.002141>

393

394 15. Coggan AR, Peterson LR. Dietary nitrate influences the contractile properties of human
395 muscle. *Exerc Sport Sci Rev.* 2018;46(4):254-261.
396 <https://doi.org/10.1249/JES.000000000000167>

397

398 16. Coggan AR, Hoffman RL, Gray DA, Moorthi RN, Thomas DP, Leibowitz JL, Thies D,
399 Peterson LR. A single dose dietary of nitrate increases maximal muscle speed and power in
400 healthy older men and women. *J Gerontol A Biol Sci Med Sci.* 2020; 75(6):1154-1160.
401 <https://doi.org/10.1093/gerona/glz156>

402

- 403 17. Ashor AW, Lara J, Siervo M. Medium-term effects of dietary nitrate supplementation on
404 systolic and diastolic blood pressure in adults: a systematic review and meta-analysis. *J*
405 *Hypertens.* 2017;35(7):1353-1359. <https://doi.org/10.1097/hjh.0000000000001305>
406
- 407 18. Siervo M, Lara J, Jajja A, Sutyarjoko A, Ashor AW, Brandt K, Qadir O, Mathers JC,
408 Benjamin N, Winyard PG, Anning C, Shore A, Gilchrist M. Ageing modifies the effects of
409 beetroot juice supplementation on 24-hour blood pressure variability: An individual
410 participant meta-analysis. *Nitric Oxide.* 2015;47(1):97-105.
411 <https://doi.org/10.1016/j.niox.2015.04.007>
412
- 413 19. Li L, Wang H, Hu L, Zhao B, Fan Z, Zhang C, Wang J, Wang S. Age associated decrease of
414 sialin in salivary glands. *Biotech Histochem* 2018;93(7):505-511.
415 <https://doi.org/10.1080/10520295.2018.1463453>
416
- 417 20. Wylie LJ, Kelly J, Bailey SJ, Blackwell JR, Skiba PF, Winyard PG, Jeukendrup AE,
418 Vanhatalo A, Jones AM. Beetroot juice and exercise: pharmacodynamic and dose-response
419 relationships. *J Appl Physiol.* 2013;115(3):325-336.
420 <https://doi.org/10.1152/jappphysiol.00372.2013>
421
- 422 21. Lundberg JO, Weitzberg E, Lundberg JM, Alving K. Intra-gastric nitric oxide production in
423 humans: measurements in expelled air. *Gut* 1994;35(11):1543-1546.
424 <https://doi.org/10.1136/gut.35.11.1543>
425

- 426 22. Obach RS, Huynh P, Allen MC, Beedham C. Human liver aldehyde oxidase: inhibition by
427 239 drugs. *J Clin Pharmacol.* 2004;44(1):7-19. <https://doi.org/10.1177/0091270003260336>
428
- 429 23. Govoni M, Jansson EA, Weitzberg E, Lundberg JO. The increase in plasma nitrite after a
430 dietary nitrate load is markedly attenuated by an antibacterial mouthwash. *Nitric Oxide.*
431 2008;19(4):333-337. <https://doi.org/10.1016/j.niox.2008.08.003>
432
- 433 24. Webb DJ, Freestone S, Allen MJ, Muirhead GJ. Sildenafil citrate and blood-pressure-
434 lowering drugs: results of drug interaction studies with an organic nitrate and a calcium
435 antagonist. *Am J Cardiol.* 1999;83(5A):21C-28C. [https://doi.org/10.1016/s0002-
436 9149\(99\)00044-2](https://doi.org/10.1016/s0002-9149(99)00044-2)
437
- 438 25. Coggan AR, Broadstreet SR, Mahmood K, Mikhalkova D, Madigan M, Bole I, Leibowitz JL,
439 Thomas DP, Thies D, Peterson LR. Dietary nitrate increases VO₂peak and performance but
440 does not alter ventilation or efficiency in patients with heart failure with reduced ejection
441 fraction. *J Card Fail.* 2018; 24(2):65-73. <https://doi.org/10.1016/j.cardfail.2017.09.004>
442
- 443 26. Steib S, Schoene D, Pfeifer K. Dose-response relationship of resistance training in older
444 adults: a meta-analysis. *Med Sci Sports Exerc.* 2010;42(5):902-914.
445 <https://10.1249/MSS.0b013e3181c34465>
446
- 447 27. Flueck JL, Bogdanova A, Mettler S, Perret C. Is beetroot juice more effective than sodium
448 nitrate? The effects of equimolar nitrate dosages of nitrate-rich beetroot juice and sodium

449 nitrate on oxygen consumption during exercise. *Appl Physiol Nutr Metab.* 2016;41(4):421-
450 429. <https://doi.org/10.1139/apnm-2015-0458>

451
452 28. Hoon MW, Jones AM, Johnson NA, Blackwell JR, Broad EM, Lundy B, Rice AJ, Burke
453 LM. The effect of variable doses of inorganic nitrate-rich beetroot juice on simulating 2,000-
454 m rowing performance in trained athletes. *Int J Sports Physiol Perform.* 2014;9(4):615-620.
455 <https://doi.org/10.1123/ijspp.2013-0207>

456
457 29. Peeling P, Cox GR, Bullock N, Burke LM. Beetroot juice improves on-water 500 m time-
458 trial performance, and laboratory-based paddling economy in national and international-level
459 kayak athletes. *Int J Sport Nutr Exerc Metab.* 2015;25(3):278-284.
460 <https://doi.org/10.1123/ijsnem.2014-0110>

461
462 30. Larsen FJ, Wietzberg E, Lundberg JO, Ekblom B. Dietary nitrate reduces maximal oxygen
463 consumption while maintaining work performance in maximal exercise. *Free Radic Biol*
464 *Med.* 2010;48(2):342-347. <https://doi.org/10.1016/j.freeradbiomed.2009.11.006>

465
466 31. Bescós R, Rodríguez FA, Iglesias X, Ferrer MD, Iborra E, Pons A. Acute administration of
467 inorganic nitrate reduces VO_{2peak} in endurance athletes. *Med Sci Sports Exerc.*
468 2011;43(10):1979-1986. <https://doi.org/10.1249/MSS.0b013e318217d439>

469

- 470 32. van Velzen AG, Sips AJAM, Schothorst RC, Lambers AC, Meulenbelt J. The oral
471 bioavailability of nitrate from nitrate-rich vegetables in humans. *Toxicol Lett.*
472 2008;181(3):177-181. <https://doi.org/10.1016/j.toxlet.2008.07.019>
473
- 474 33. Gholami F, Rahamini L, Amirnezhad F, Cheraghi K. High doses of sodium nitrate prior to
475 exhaustive exercise increases plasma peroxynitrite levels in well-trained subjects:
476 randomized, double-blinded, crossover study. *Appl Physiol Nutr Metab.* 2019;44(12):1305-
477 1310. <https://doi.org/10.1139/apnm-2018-0816>
478
- 479 34. Wylie LJ, Park JW, Vanhatalo A, Kadach S, Black MI, Stoyanov Z, Schechter AN, Jones
480 AM, Pikhova B. Human skeletal muscle nitrate store: influence of dietary nitrate
481 supplementation and exercise. *J Physiol.* 2019;597(23):5565-5576.
482 <https://doi.org/10.1113/JP278076>
483
- 484 35. Damacena-Angelis C, Oliveira-Paula GH, Pinheiro LC, Crevelin EJ, Portella RL, Moraes
485 LAB, Tanus-Santos JE. Nitrate decreases xanthine oxidoreductase-mediated nitrite reductase
486 activity and attenuates vascular and blood pressure responses to nitrite. *Redox Biol.*
487 2017;12(8):291-299. <https://doi.org/10.1016/j.redox.2017.03.003>
488
- 489 36. Nogueira L, Figueiredo-Freitas C, Casimiro-Lopes G, Magdesian MH, Assreuy J, and
490 Sorenson MM. Myosin is reversibly inhibited by S-nitrosylation. *Biochem J.* 2009;
491 424(2):221-231. <https://doi.org/10.1042/BJ20091144>
492

- 493 37. Kelly J, Fulford J, Vanhatalo A, et al. Effects of short-term dietary nitrate supplementation
494 on blood pressure, O₂ uptake kinetics, and muscle and cognitive function in older adults. *Am*
495 *J Physiol Regul Integr Comp Physiol.* 2013;304(2):R73–R83.
496 <https://doi.org/10.1152/ajpregu.00406.2012>
497
- 498 38. Kim DJ, Roe CA, Somani YB, Moore DJ, Barrett MA, Flanagan M, Kim-Shapiro DB, Basu
499 S, Muller MD, Proctor DN. Effects of acute dietary nitrate supplementation on aortic blood
500 pressures and pulse wave characteristics in post-menopausal women. *Nitric Oxide.*
501 2019;85(4):10-16. <https://doi.org/10.1016/j.niox.2019.01.008>
502
- 503 39. Hughes WE, Ueda K, Treichler DP, Casey DP. Effects of acute dietary nitrate
504 supplementation on aortic blood pressure and aortic augmentation index in young and older
505 adults. *Nitric Oxide.* 2016;59(9):21-27. <https://doi.org/10.1016/j.niox.2016.06.007>
506
- 507 40. Ashor AW, Shannon OM, Werner A-D, Sciallo F, Giallard CN, Cassel KS, Seal CJ, Zheng
508 D, Mathers JC, Siervo M. Effects of inorganic nitrate and vitamin C co-supplementation on
509 blood pressure and vascular function in younger and older healthy adults: A randomised
510 double-blind crossover trial. *Clin Nutr.* 2019;39(3):708-717.
511 <https://doi.org/10.1016/j.clnu.2019.03.006>

512 Table 1. Effect of varying doses of dietary NO₃⁻ on plasma NO₃⁻, plasma NO₂⁻, breath NO, and
 513 plasma 3-nitrotyrosine in healthy older subjects.

	Dose of NO ₃ ⁻ (μmol/kg)	Pre <u>ingestion</u>	Time of measurement		
			1 h post <u>ingestion</u>	2 h post <u>ingestion</u>	10 min post <u>exercise</u>
Plasma NO ₃ ⁻ (μmol/L)	0	55±10	57±5	67±6	66±5
	200	40±5	523±52 [‡]	624±53 [‡]	628±47 [‡]
	400	34±5	793±73 ^{‡¶}	1184±89 ^{‡¶}	1296±94 ^{‡¶}
Plasma NO ₂ ⁻ (μmol/L)	0	0.31±0.05	0.30±0.02	0.33±0.04	0.35±0.05
	200	0.31±0.04	0.46±0.07	0.53±0.07 [*]	0.82±0.18
	400	0.34±0.06	0.48±0.06	0.95±0.18 ^{*§}	1.22±0.15 [*]
Breath NO (ppb)	0	19±3	22±3	25±3	21±3
	200	18±3	39±6 [*]	43±7 [*]	50±10 [*]
	400	18±3	31±4 [†]	36±4 [†]	36±6 [*]
3-Nitrotyrosine (nmol/L)	0	177±20	153±18	170±19	217±27
	200	170±22	158±19	176±23	216±27
	400	237±25	209±22	198±26	250±34

514 Values are mean±SE for n=9. Significantly different from 0 μmol/kg dose: ^{*}P<0.05, [†]P<0.01,

515 [‡]P<0.001. Significantly different from 200 μmol/kg dose: [§]P<0.05, [¶]P<0.001.

516 Table 2. Effect of varying doses of dietary NO₃⁻ on peak knee extensor torque and power as a
 517 function of velocity in healthy older subjects.

		Dose of NO ₃ ⁻ (μmol/kg)	Angular velocity (rad/s)				
			<u>0</u>	<u>1.57</u>	<u>3.14</u>	<u>4.71</u>	<u>6.28</u>
Peak torque (Nm/kg)	0	1.79±0.15	1.21±0.10	0.91±0.06	0.75±0.06	0.55±0.06	
	200	1.86±0.15	1.24±0.07	0.92±0.06	0.78±0.06	0.61±0.06 [†]	
	400	1.78±0.12	1.24±0.07	0.90±0.05	0.74±0.06	0.56±0.06	
Peak power (W/kg)	0	0.00±0.00	1.97±0.15	2.91±0.22	3.59±0.30	3.46±0.45	
	200	0.00±0.00	1.95±0.11	2.89±0.20	3.69±0.27	3.83±0.37 [†]	
	400	0.00±0.00	1.94±0.11	2.84±0.17	3.48±0.28	3.49±0.39	

518 Values are mean±SE for n=9. Significantly different from 0 or 400 μmol/kg doses: [†]P<0.01.

519 Table 3. Effect of varying doses of dietary NO₃⁻ on heart rate and blood pressure in healthy older
 520 subjects.

	Dose of NO ₃ ⁻ (μ mol/kg)	Pre <u>ingestion</u>	Time of measurement		
			1 h post <u>ingestion</u>	2 h post <u>ingestion</u>	10 min post <u>exercise</u>
Heart rate (beats/min)	0	73 \pm 4	72 \pm 3	70 \pm 3	73 \pm 3
	200	71 \pm 4	74 \pm 3	70 \pm 3	73 \pm 2
	400	72 \pm 3	70 \pm 3	71 \pm 3	74 \pm 3
Systolic blood pressure (mmHg)	0	131 \pm 5	122 \pm 4	122 \pm 3	125 \pm 4
	200	130 \pm 4	122 \pm 6	121 \pm 5	119 \pm 6
	400	134 \pm 4	121 \pm 4	118 \pm 5	118 \pm 6
Diastolic blood pressure (mmHg)	0	70 \pm 2	68 \pm 2	68 \pm 3	69 \pm 2
	200	69 \pm 4	67 \pm 3	67 \pm 3	68 \pm 4
	400	69 \pm 3	62 \pm 3	64 \pm 4	65 \pm 3
Mean arterial pressure (mmHg)	0	90 \pm 2	86 \pm 2	86 \pm 2	87 \pm 2
	200	90 \pm 3	85 \pm 3	85 \pm 3	85 \pm 3
	400	90 \pm 3	82 \pm 3	82 \pm 3	82 \pm 3

521 Values are mean \pm SE for n=9.

522 **Figure legends**

523





524 Figure 1. Changes (Δ) in plasma nitrate (NO_3^- ; *panel A*), nitrite (NO_2^- ; *panel B*), breath nitric
525 oxide (NO; *panel C*), and plasma 3-nitrotyrosine (3-NT; *panel D*) in response to varying doses of
526 dietary NO_3^- in healthy older subjects. Values are mean \pm SE for n=9. Significantly different from
527 0 $\mu\text{mol/kg}$ dose: *P<0.05, ‡P<0.001. Significantly different from 200 $\mu\text{mol/kg}$ dose: §P<0.05,
528 ¶P<0.001.





529

530 Figure 2. Individual absolute and relative changes (Δ) in maximal knee extensor power (Pmax;
531 *panels A and B*) and velocity (Vmax; *panels C and D*) in response to varying doses of dietary
532 nitrate (NO_3^-) in healthy older subjects.


533

534 Figure 3. Proposed explanation for the effect of varying doses of dietary nitrate (NO_3^-) on muscle
535 contractile function in healthy older subjects. A lower dose of NO_3^- (i.e., 200 $\mu\text{mol/kg}$) is
536 hypothesized to result in a significant increase in muscle NO_3^- concentration, which is reduced
537 by xanthine oxidoreductase (XOR) to nitrite (NO_2^-) and then to nitric oxide (NO), leading to
538 significant improvements in maximal knee extensor power (Pmax) and velocity (Vmax) and also
539 to an increase in 3-nitrotyrosine (3-NT) formation. In contrast, a higher dose of NO_3^- (i.e.,
540 400 $\mu\text{mol/kg}$) actually results in less of an increase in NO production, due to substrate
541 competition between NO_3^- and NO_2^- for XOR. As a result, Pmax, Vmax, and 3-NT are
542 unchanged, or possibly even diminished.





Low Dose



High Dose

